Athleticomed Sp. z o.o.
- Address
- lock Available on a paid plan
Nervous System Diseases and Migraine Research
At Athleticomed Sp. z o.o. in Bydgoszcz, much of the clinical research focuses on nervous system diseases, especially different forms of migraine in children, adolescents, and young adults. These studies are exploring both prevention and symptom control, with the aim of improving how migraine is managed over time.
- Studies in chronic migraine and episodic migraine in pediatric and adolescent populations
- Research on menstrual migraine and migraine prevention in younger patients
- Trials evaluating whether new treatments can reduce migraine days and improve day-to-day functioning
Overall, this therapeutic area is centered on testing new options for migraine prevention and assessing their safety and effectiveness in younger age groups.
Nutritional and Metabolic Diseases and Weight Management Research
The site also conducts research in nutritional and metabolic diseases, with a focus on overweight and obesity. These trials are designed to understand whether emerging therapies can support meaningful and sustained weight loss in adults, including people with and without type 2 diabetes.
- Studies in overweight and obesity in adult participants
- Research that examines weight loss outcomes over time
- Trials aimed at evaluating the effectiveness and safety of new approaches to weight management
This area of research is focused on finding better treatment options for long-term weight control and related metabolic health concerns.
Pediatric and Adolescent Clinical Trials
A notable part of the research portfolio at Athleticomed Sp. z o.o. involves studies in children and adolescents, particularly for migraine. These trials are helping determine how well new therapies work in younger patients while also paying close attention to safety and tolerability.
- Clinical research in children and adolescents with migraine disorders
- Evaluations of preventive treatments for chronic and episodic migraine
- Studies intended to support age-appropriate treatment options for younger patients
These trials are important for expanding treatment choices where evidence in pediatric populations is still limited.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Athleticomed Sp. z o.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine | AbbVie Deutschland GmbH & Co. KG | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 6 | Unknown | 2023-11-08 | 2025-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.